Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
- Astellas to Adopt International Financial Reporting Standards as of March 2014
March 1, 2013
- DSP’s US Subsidiary Sunovion Announces FDA Acceptance of NDA Resubmission for Epilepsy Treatment Stedesa
March 1, 2013
- Takeda to Develop New Compounds for Autoimmune Diseases Jointly with Resolve Therapeutics of US
March 1, 2013
- Taiho Files for Novel Anticancer Agent TAS-102 in Japan
March 1, 2013
- BMKK, Pfizer Japan Launch, Copromote Anti-Xa Agent Eliquis
March 1, 2013
- Shionogi Receives FDA Approval for Dyspareunia Treatment, Plans its Launch in June
February 28, 2013
- Gilenya Achieved Blockbuster Status in 2012; Canagliflozin Will Be Next: Pres. Tsuchiya of MTPC
February 28, 2013
- MTPC Files for Expanded Combination-Use Indication for DPP-4 Inhibitor Tenelia
February 28, 2013
- GSK Launches Anti-Malaria Drug Malarone in Japan
February 27, 2013
- Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
- Combined Sales of Januvia and Glactiv Break 110 Billion Yen in 2012: IMS Japan
February 26, 2013
- Janssen Files World’s 1st Application for Hepatitis C Treatment Simeprevir in Japan
February 26, 2013
- 3-Drug H. pylori Eradication Therapy Receives Additional Indication for H. pylori Gastritis
February 25, 2013
- Zeria to Launch Hypophosphatemia Treatment Phosribbon Combination Granules on March 4
February 25, 2013
- MTPC Calls for Proper Use of Telavic Following Reports of Serious Infections
February 25, 2013
- LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
- Lotriga, Equa, Aimix Most Promoted Products in GP, HP Markets in January: Rep Track Survey
February 22, 2013
- Astellas Files for Additional Indication for Dormicum Based on Data from Public Domain
February 22, 2013
- Shionogi Settles Lawsuit over Royalties Payment with US Firm InterMune
February 22, 2013
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…